#oncology
6 stories
BioNTech SE Shifts Focus
BioNTech SE pivots from pandemic vaccines to oncology with $19B cash and 33 trials.
Seekingalpha · 1m
Pyxis Oncology Stock Bullish
Pyxis Oncology's MICVO drug shows promise for cancer treatment.
Seekingalpha · 1m
Nanobiotix Cash Runway Meets Clinical Progress
Nanobiotix's cash runway until 2029 supports JNJ-1900 trials amid clinical progress.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m
Zydus Lifesciences Growth Strategy
Zydus forecasts steady growth for five years as innovation matures.
The Economic Times · 1m
Zydus Targets New Growth Areas
Zydus Lifesciences plans to expand into specialty medicines and biologics while maintaining US generics.
The Economic Times · 1m
The lump rule your doctor was taught is wrong
An oncologist breaks down why the classic 'hard and painless' cancer lump is a myth, and which lump she never ignores.
Newsweek · 1m